Sjoerd H. van der Burg

Leiden University Medical Center — Netherlands

Immunology and Microbiology · Life Sciences

96h-index33.1kcitations790works2.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(396), Cancer Immunotherapy and Biomarkers(234), CAR-T cell therapy research(194), Immune Cell Function and Interaction(157), Cervical Cancer and HPV Research(134)

Publications790 total

High-throughput epitope screening of the Human Cytomegalovirus immediate early protein 2 identifies promising antigenic T cell targets
2026Open Access
REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer
Nature Communications·2025· 1 citedOpen Access
Supplementary Figure S6 from Neoantigen Targetability in Progressive Advanced Melanoma
2025Open Access
Supplementary Data MS2 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV<sup>+</sup> Men
2025Open Access
Supplementary Table S2 from Neoantigen Targetability in Progressive Advanced Melanoma
2025Open Access
Supplementary Figure S4 from Neoantigen Targetability in Progressive Advanced Melanoma
2025Open Access
Supplementary Figure S2 from Neoantigen Targetability in Progressive Advanced Melanoma
2025Open Access
Supplementary Table S4 from Neoantigen Targetability in Progressive Advanced Melanoma
2025Open Access
Supplementary Figure S1 from Neoantigen Targetability in Progressive Advanced Melanoma
2025Open Access
Supplementary Figure S5 from Neoantigen Targetability in Progressive Advanced Melanoma
2025Open Access
Supplementary Data MS1 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV<sup>+</sup> Men
2025Open Access
Supplementary Data FS2 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV<sup>+</sup> Men
2025Open Access
Supplementary Table S5 from Neoantigen Targetability in Progressive Advanced Melanoma
2025Open Access
Supplementary Methods S1 from Neoantigen Targetability in Progressive Advanced Melanoma
2025Open Access
Supplementary Data FS3 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV<sup>+</sup> Men
2025Open Access
Supplementary Figure S3 from Neoantigen Targetability in Progressive Advanced Melanoma
2025Open Access
Supplementary Data TS3 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV<sup>+</sup> Men
2025Open Access
Supplementary Data FS1 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV<sup>+</sup> Men
2025Open Access
Supplementary Table S1 from Neoantigen Targetability in Progressive Advanced Melanoma
2025Open Access
Supplementary Data TS2 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV<sup>+</sup> Men
2025Open Access
page 1 of 40Next →

Frequent Co-authors

Cornelis J.M. Melief(22), Marij J.P. Welters(17), Rienk Offringa(15), Gemma G. Kenter(13), Jan W. Drijfhout(12), Gert Jan Fleuren(10), Thorbald van Hall(9), Jaap Oostendorp(8), Ferry Ossendorp(6), A. Rob P.M. Valentijn(6), Sytse J. Piersma(6), Dorien M. A. Berends-van der Meer(5), Judith R. Kroep(5), Jeanette M. van der Hulst(5), Kees L. M. C. Franken(5), Hans W. Nijman(5), Annelies P.G. Vloon(4), Lorraine M. Fathers(4), Cécile Gouttefangeas(4), Cedrik M. Britten(4)